ImmunityBio Inc.

IBRX06 Dec 2024
Healthcare
$4.8
-0.04 (-3.59%)
Lowest Today
$4.54
Highest Today
$4.85
Today’s Open
$4.8
Prev. Close
$4.74
52 Week High
$10.53
52 Week Low
$3.1
To Invest in ImmunityBio Inc.

ImmunityBio Inc.

Healthcare
IBRX06 Dec 2024
-0.04 (-3.59%)
1M
3M
6M
1Y
5Y
Low
$4.54
Day’s Range
High
$4.85
4.54
52 Week Low
$3.1
52-Week Range
52 Week High
$10.53
3.1
1 Day
-
1 Week
-9.78%
1 month return
-15.93%
3 month return
+35.45%
6 month return
-25.16%
1 Year return
+23.04%
3 Years return
-19.91%
5 Years return
+188.92%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
2.43
BlackRock Inc
1.64
State Street Corp
1.24
Vanguard Total Stock Mkt Idx Inv
0.82
SPDR® S&P Biotech ETF
0.72
Vanguard Small Cap Index
0.63
iShares Russell 2000 ETF
0.58

Market Status

Fundamentals
Market Cap
3302.98 mln
PB Ratio
0
PE Ratio
0
Enterprise Value
3915.53 mln
Total Assets
504.45 mln
Volume

Company Financials

Fund house & investment objective

Company Information
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Organisation
ImmunityBio Inc.
Employees
672
Industry
Biotechnology
CEO
Mr. Richard Gerald Adcock
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step